Regeneron Pharmaceuticals Inc (REGN)
1062.91
-8.71
(-0.81%)
USD |
NASDAQ |
Jun 26, 09:50
Regeneron Pharmaceuticals SG&A Expense (Annual): 2.631B for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.631B |
| December 31, 2022 | 2.116B |
| December 31, 2021 | 1.825B |
| December 31, 2020 | 1.346B |
| December 31, 2019 | 1.342B |
| December 31, 2018 | 1.127B |
| December 31, 2017 | 1.320B |
| December 31, 2016 | 1.178B |
| December 31, 2015 | 838.53M |
| December 31, 2014 | 519.27M |
| December 31, 2013 | 346.39M |
| December 31, 2012 | 210.76M |
| December 31, 2011 | 117.26M |
| December 31, 2010 | 65.20M |
| December 31, 2009 | 52.92M |
| December 31, 2008 | 48.88M |
| December 31, 2007 | 37.86M |
| Date | Value |
|---|---|
| December 31, 2006 | 25.89M |
| December 31, 2005 | 25.48M |
| December 31, 2004 | 17.06M |
| December 31, 2003 | 14.78M |
| December 31, 2002 | 12.53M |
| December 31, 2001 | 9.607M |
| December 31, 2000 | 8.309M |
| December 31, 1999 | 6.40M |
| December 31, 1998 | 5.80M |
| December 31, 1997 | 5.80M |
| December 31, 1996 | 5.90M |
| December 31, 1995 | 5.80M |
| December 31, 1994 | 8.50M |
| December 31, 1993 | 46.30M |
| December 31, 1992 | 27.80M |
| December 31, 1991 | 3.30M |
| December 31, 1990 | 1.70M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
1.342B
Minimum
2019
2.631B
Maximum
2023
1.852B
Average
1.825B
Median
2021
SG&A Expense (Annual) Benchmarks
| Amgen Inc | 6.179B |
| Vertex Pharmaceuticals Inc | 1.137B |
| Eli Lilly and Co | 6.941B |
| Pfizer Inc | 14.77B |
| Moderna Inc | 1.549B |